Gilead Sciences has named Roche Holding's Daniel O’Day as its new chief executive.
O’Day, now head of Roche’s pharmaceuticals business, joined the company in 1987 and held various roles in the U.S. before moving in 1998 to headquarters in Basel, Switzerland.
Gilead is hoping that O’Day’s three decades of oncology and global commercial expertise at Roche will help the company build out its global presence, particularly in oncology and inflammation.
As previously announced, Gilead’s CEO John Milligan and Chairman John Martin will step down at the end of the year.
Read the press release